证券代码：000661 证券简称：长春高新 公告编号：2025-065 长春高新技术产业（集团）股份有限公司 关于授权公司管理层启动公司境外发行股份（H 股）并在香港联合 交易所有限公司上市相关筹备工作的提示性公告 2025 年 7 月 2 日 长春高新技术产业（集团）股份有限公司（以下简称"公司"）于 2025 年 6 月 30 日召开第十一届董事会第十次会议，审议通过了《关于授权公司管理层启动 公司境外发行股份（H 股）并在香港联合交易所有限公司上市相关筹备工作的议 案》。 为深化公司全球化战略布局，加快公司国际化进程，增强公司在境外融资能 力，进一步提升公司国际品牌形象，公司拟在境外发行股份（H 股）并在香港联 合交易所有限公司（以下简称"香港联交所"）上市（以下简称"本次 H 股上市"）， 公司董事会授权公司管理层启动本次 H 股上市的前期筹备工作。公司已按合规 流程确定并启动与相关中介机构的沟通与合作，目前公司正在与相关中介机构就 本次 H 股上市的具体推进工作进行商讨，关于本次 H 股上市的细节尚未确定。 根据《深圳证券交易所股票上市规则》《境内企业境外发行证券和上市管理 试行办法》等法律法规的要 ...

1、经长春高新技术产业（集团）股份有限公司（以下简称"公司"）半数以上 董事同意，公司第十一届董事会第十次会议于 2025 年 6 月 26 日以电话方式发出 会议通知。 2、本次董事会于 2025 年 6 月 30 日 13:30 以现场结合通讯方式召开。 3、本次会议应参与表决董事 9 名，实际参与表决董事 9 名。 证券代码：000661 证券简称：长春高新 公告编号：2025-064 长春高新技术产业（集团）股份有限公司 第十一届董事会第十次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、董事会会议召开情况 三、备查文件 1、经与会董事签字并加盖董事会印章的董事会决议； 4、会议由董事长姜云涛先生主持，公司监事、高级管理人员列席了本次会 议。 5、本次会议的召开符合有关法律、行政法规、部门规章、规范性文件和《公 司章程》的规定。 二、董事会会议审议情况 经与会董事认真讨论，本次会议审议通过《关于授权公司管理层启动公司境 外发行股份（H 股）并在香港联合交易所有限公司上市相关筹备工作的议案》。 表决结果：9 票同意，0 票反对，0 票弃 ...

Group 1 - A-share annual report dividend trend continues, with 198 companies distributing nearly 699 billion yuan this week [1] - China Ping An leads with a dividend of 293.34 billion yuan, followed by China General Nuclear Power and GF Securities with 47.97 billion yuan and 30.42 billion yuan respectively [1] - Over 2875 companies have completed annual report dividends, totaling nearly 977.5 billion yuan, accounting for 59.5% of the total annual dividend amount [1] Group 2 - The Shanghai Stock Exchange announced that cash dividends for Shanghai-listed companies in 2024 are expected to reach 1.8 trillion yuan, a historical high, with a dividend payout ratio of 35.6% [1][27] - Approximately 500 companies are set to issue interim dividends to meet investor cash flow needs [27] - In the past three years, 68 companies have cumulatively distributed over 10 billion yuan in cash dividends, and 872 companies have maintained a dividend payout ratio exceeding 30% for three consecutive years [27] Group 3 - The CSI Dividend ETF (515080) announced a dividend of 0.15 yuan per ten shares, with a distribution ratio of 0.99% [24][26] - This marks the 13th dividend distribution since the ETF's inception, with a cumulative dividend amount of 3.5 yuan per ten shares [26] - The ETF's annual dividend ratios over the past five years have been 4.53%, 4.14%, 4.19%, 4.78%, and 4.66% respectively [26] Group 4 - The CSI Dividend Index's total cash dividend for 2024 exceeded 920 billion yuan, setting a new historical high with a payout ratio of over 36% [20][21] - The index includes 100 constituent stocks, with China Shenhua distributing over 449 billion yuan [22][23] - The dividend distribution is part of a broader trend of increasing cash dividends among listed companies [20][21]

Core Viewpoint - The company has announced its 2024 annual profit distribution plan, which includes a cash dividend of 26 RMB per 10 shares, based on a total share capital of 407,937,529 shares, excluding repurchased shares [2][3][7] Summary by Sections Profit Distribution Plan - The profit distribution plan was approved at the 2024 annual general meeting, with a cash dividend of 26 RMB per 10 shares (including tax) based on 402,874,312 shares after excluding repurchased shares [2][3] - The total cash dividend amount is calculated as 1,044,457,471.2 RMB, derived from the participating shares multiplied by the distribution ratio [7] Share Capital and Repurchase - The total share capital of the company is 407,937,529 shares, with 6,223,117 shares held in the repurchase account, which do not participate in the profit distribution [1][2] - The distribution will be based on 401,714,412 shares after excluding the repurchased shares [3][7] Dividend Payment Details - The cash dividends will be distributed on July 4, 2025, with the record date set for July 3, 2025 [4][5] - The cash dividends will be directly credited to the accounts of shareholders through their custodial securities companies [5][6] Taxation Information - Different tax rates apply for various categories of shareholders, with specific provisions for Hong Kong investors and domestic investors [3][4] Adjustments and Calculations - The ex-dividend price will be adjusted based on the cash dividend amount of 2.5603368 RMB per share, calculated from the total cash dividend divided by the total share capital [7]

证券代码：000661 证券简称：长春高新 公告编号：2025-063 长春高新技术产业（集团）股份有限公司 2024 年年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 截止本公告日，长春高新技术产业（集团）股份有限公司（以下简称"公司、 本公司"）总股本为 407,937,529 股，回购专用证券账户持有的股份数量为 6,223,117 股。根据《公司法》的规定，回购专用证券账户股份不享有利润分配 和资本公积金转增股本的权利。公司本次权益分派以公司总股本 407,937,529 股扣除当前回购专用证券账户持有的股份6,223,117股后的401,714,412股为基 数，向全体股东每 10 股派发现金红利 26 元（含税），公司本次实际现金分红的 总金额 = 实际参与分配的总股本×分配比例，即 1,044,457,471.2 元 =401,714,412 股×2.6 元/股。因公司回购股份不参与分红，本次权益分派实施 后，实施权益分派前后公司总股本保持不变，现金分红总额分摊到每一股的比例 将减小，因此，本次权益分派实施后除权 ...

Group 1: Investment Funds and Initiatives - Changchun Xinghe Runxin Venture Capital Center, initiated by CITIC Construction Investment and several partners, has been registered with the Asset Management Association of China, focusing on the biomedical industry in Jilin Province [2] - A total scale of 1 billion yuan industrial software special fund was signed at the 2025 Nanjing Software Conference, highlighting the importance of industrial software in digital transformation and smart manufacturing [3] - Zhongke Chuangxing successfully issued a 400 million yuan targeted technology innovation bond, with a 2.10% interest rate, showcasing market confidence in its investment strategy [4] Group 2: Market Trends and Performance - The number of innovative drugs approved in China increased from 3 in 2015 to 39 in 2024, marking a 12-fold increase and positioning China as the second globally in innovative drug approvals [8] - The total amount of cross-border business development transactions by Chinese pharmaceutical companies reached 63.5 billion USD in 2024, a year-on-year increase of 22.59% [8] - The Hang Seng Technology Index rose by 14.9%, significantly outperforming major global markets, indicating a strong recovery in the Hong Kong capital market [8] Group 3: Strategic Developments - Zhengzhou Economic Development Zone's first industrial venture capital mother fund has been registered, with a total scale of 5 billion yuan, focusing on sectors like new energy and high-end intelligent equipment [9][10] - The Xiong'an Artificial Intelligence Industrial Park aims to create a comprehensive ecosystem for AI innovation, supported by a 10 billion yuan investment fund [10][11] - Wuhan's government has released an action plan to enhance the development of technology finance, optimizing the evaluation mechanism for government investment funds [12]

Core Viewpoint - The article discusses the significant developments in the field of shingles vaccines in China, highlighting the price reduction initiatives and the emergence of domestic vaccine production, particularly by Changchun Baike Biotechnology Co., Ltd. [5][6] Group 1: Vaccine Market Dynamics - The shingles vaccine market in China is experiencing a price reduction trend, driven by the "Healthy China" strategy, which aims to enhance public health through affordable vaccination programs [5]. - There are currently two approved shingles vaccines in China: one imported and one domestically produced by a company based in Changchun, Jilin [5][6]. Group 2: Company Innovations and Developments - Changchun Baike Biotechnology has launched the first domestically developed live attenuated shingles vaccine for individuals aged 40 and above, breaking the monopoly of imported vaccines in the market [6]. - The parent company, Changchun High-tech Industry (Group) Co., Ltd., has shifted its focus towards innovation in the biopharmaceutical sector, investing over 8.5 billion yuan in research and development [6][8]. Group 3: Regional Industry Growth - The biopharmaceutical industry in Changchun is supported by a robust infrastructure and educational resources, including institutions like the Chinese Academy of Sciences and several key universities [8]. - The biopharmaceutical and life health industry in Changchun is projected to achieve a production value of 110 billion yuan in 2024, reflecting a year-on-year growth of 12.5% [8][11]. Group 4: Future Prospects - The "Yongchun Biopharmaceutical City" is under construction, with 33 projects and a total investment of 15.2 billion yuan, expected to generate a production value of 60 billion yuan by 2035 [11]. - The local government has introduced a three-year action plan to further develop the biopharmaceutical and life health industry as a new growth engine for the city's economy [11][13].

证券代码：000661 证券简称：长春高新 公告编号：2025-062 长春高新技术产业（集团）股份有限公司 关于子公司流感病毒裂解疫苗（BK-01佐剂） 临床试验申请获得批准的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 近日，长春高新技术产业（集团）股份有限公司（以下简称"公司"）子公司长 春百克生物科技股份公司（以下简称"百克生物"）收到国家药品监督管理局核准签 发的《药物临床试验批准通知书》，百克生物流感病毒裂解疫苗（BK-01 佐剂）临床 试验申请获得批准，现将相关情况公告如下： 一、《药物临床试验批准通知书》的主要内容 受理号：CXSL2500239 通知书编号：2025LP01603 药品名称：流感病毒裂解疫苗（BK-01 佐剂） 结论：同意开展预防疫苗相关型别流感病毒引起的流行性感冒的临床试验 批准日期：2025 年 06 月 19 日 二、药品的其它情况 流感是由流感病毒引起的一种急性呼吸道传染病，流感病毒因其基因多变性、宿 主多样性，可在人群中广泛传播，每年可造成约 300 万～500 万严重病例和 29 万～ 65 万例死亡。世界 ...

证券代码：000661 证券简称：长春高新 公告编号：2025-060 长春高新技术产业（集团）股份有限公司 关于子公司 GenSci134 注射液临床试验申请获得批准的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 近日，长春高新技术产业（集团）股份有限公司（以下简称"公司"）子公 司——长春金赛药业有限责任公司（以下简称"金赛药业"）收到国家药品监督 管理局核准签发的《药物临床试验批准通知书》，金赛药业 GenSci134 注射液的 境内生产药品注册临床试验申请获得批准，现将相关情况公告如下： 一、药品的基本情况 产品名称： GenSci134 注射液 申请事项：境内生产药品注册临床试验 生长激素缺乏症是由垂体发育异常、颅脑损伤、遗传基因突变、下丘脑功能 障碍、慢性系统性疾病等因素引起的生长发育及代谢障碍，可在一生中各个阶段 发生。成人生长激素缺乏常合并多种并发症，带来诸多危害。基于治疗现状， AGHD 患者需要长期甚至终身替代治疗，存在未被满足的临床需求。 综上所述，GenSci134 注射液具有潜在治疗 AGHD 的成药性，本次临床试验 申请的获 ...

产品名称：醋酸甲地孕酮口服混悬液 商品名称：美适亚® 证券代码：000661 证券简称：长春高新 公告编号：2025-061 长春高新技术产业（集团）股份有限公司 关于醋酸甲地孕酮口服混悬液（美适亚® ） 药物临床试验申请获得批准的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 近日，长春高新技术产业（集团）股份有限公司（以下简称"公司"）子 公司——长春金赛药业有限责任公司（以下简称"金赛药业"）收到国家药品 监督管理局核准签发的《药物临床试验批准通知书》，授权经销合作产品醋酸 甲地孕酮口服混悬液（美适亚®）的境外生产药品注册临床试验申请获得批准， 现将本次获批相关情况公告如下： 一、药品的基本情况 申请事项：境外生产药品注册临床试验申请 受理号：JXHL2500056 申请人：保盛药业股份有限公司（中国台湾） 境内责任人/注册代理机构：长春金赛药业有限责任公司 审批结论：同意本品开展临床试验 适应症：预防化疗引起的恶心呕吐 二、药品的其它情况 化疗所致的恶心、呕吐（CINV）是抗肿瘤治疗的常见不良反应之一，70% 以上的抗肿瘤患者会出现不同程度的恶心 ...